Roth Capital Has Bullish Forecast for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Roth Capital raised their FY2024 earnings estimates for Tenax Therapeutics in a research note issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff now anticipates that the specialty pharmaceutical company will post earnings per share of ($1.16) for the year, up from their prior forecast of ($6.01). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $1.82 EPS and FY2028 earnings at $3.08 EPS.

Other research analysts have also issued research reports about the company. Leerink Partners assumed coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price objective for the company. Guggenheim initiated coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. William Blair began coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They issued an “outperform” rating for the company. StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating for the company. Finally, Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Tenax Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $4.86 on Monday. The stock has a 50 day simple moving average of $4.04 and a 200-day simple moving average of $3.71. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $33.44.

Institutional Investors Weigh In On Tenax Therapeutics

A number of large investors have recently added to or reduced their stakes in TENX. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics during the third quarter worth about $101,000. Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $173,000. 1.67% of the stock is owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.